Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

UDG Healthcare on the mend as RBC Capital kicks off coverage with an ‘outperform’ rating

UDG shares have lost a third of their value over the past year, but RBC reckons the sell-off, while justified initially, has been overdone
RBC has set a price target of 800p per share, 20% above where the stock currently sits

Mid-tier Canadian investment bank RBC Capital has initiated coverage of pharma marketing specialist UDG Healthcare PLC (LON:UDG) with an ‘outperform’ rating.

UDG shares have fallen by a third over the past 12 months, which RBC puts down to “headwinds to individual businesses”, although analysts there think the sell-off now looks “overdone”.

READ: UDG Healthcare sells non-core Aquilant division and reviews Ashfield business

“With improving profit quality mix only set to continue and visible tailwinds this looks like a good time to take advantage,” they wrote in a note to clients.

When UDG reports its full-year results at the end of this month, the number crunchers reckon they should show a 1.3% rise in underlying earnings (EBOT). Growth is then expected to pick up to 3.9% next year, before heading up to 8.5% in 2020.

The RBC analysts note that UDB trades at a 20% discount to its peers, but are convinced that valuation is set to improve. Alongside their ‘outperform’ rating, they have kicked off with an 800p price target – some 20% higher from where the shares currently sit.

In late-morning trading, the stock was up 2.6% to 660p.

View full UDG profile View Profile

UDG Healthcare Timeline

Related Articles

cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use